Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Sarepta Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Sarepta Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Sarepta Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Sarepta Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Sarepta Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Sarepta Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 12
Asset Purchase 12
Sarepta Therapeutics to Acquire Manufacturing Plant in Massachusetts from Eisai for USD15 Million 12
Partnerships 13
InVitae Expands Partnership with Sarepta Therapeutics 13
Sarepta Therapeutics Enters into Partnership with Myonexus Therapeutics 14
Sarepta Therapeutics Enters into Research Agreement with Duke University 15
Sarepta Therapeutics Enters into Research Agreement with Genethon 16
Sarepta Therapeutics Enters into Research Agreement with Nationwide Children’s Hospital 17
Catabasis Pharma Enters into Agreement with Sarepta Therapeutics 18
Murdoch University Enters into Research Agreement with Sarepta Therapeutics 19
Sarepta Therapeutics Enters into Agreement with Flagship Biosciences 20
Sarepta Therapeutics Enters Into Co-Development Agreement With University College London 21
Licensing Agreements 22
Sarepta Therapeutics Enters into License Agreement with Lysogene 22
Sarepta Therapeutics to Enter into Option Agreement with Nationwide Children’s Hospital 23
Sarepta Therapeutics Enters into Licensing Agreement with Lacerta Therapeutics 24
Sarepta Therapeutics Enters into Licensing Agreement with BioMarin Pharma 25
Sarepta Therapeutics Enters into Licensing Agreement with Nationwide Children’s Hospital 27
Sarepta Therapeutics Enters into Licensing Agreement with Summit Therapeutics 28
Sarepta Therapeutics Enters Into Licensing Agreement With University Of Western Australia For Duchenne Muscular Dystrophy 29
Equity Offering 31
Sarepta Therapeutics to Raise USD500 Million in Public Offering of Shares 31
Sarepta Therapeutics Prices Public Offering of Shares for USD325 Million 32
Sarepta Therapeutics Prices Public Offering of Shares for USD300 Million 34
Sarepta Therapeutics to Raise USD37.5 Million in Public Offering of Shares 36
Sarepta Therapeutics Raises USD126.8 Million in Public Offering of Shares 37
Sarepta Therapeutics Completes Public Offering Of Shares For US$100.7 Million 39
Sarepta Therapeutics Raises USD125 million in Public Offering Of Shares 41
Sarepta Therapeutics Completes Public Offering Of Common Stock For US$125 Million 42
Sarepta Therapeutics Completes Private Placement Of Shares 44
Debt Offering 45
Sarepta Therapeutics Announces Exercise of Initial Purchasers’ Option for USD95 Million in Private Placement of Notes Due 2024 45
Asset Transactions 46
Sarepta Therapeutics Sells Pediatric Disease Priority Review Voucher 46
Sarepta Therapeutics Inc – Key Competitors 47
Sarepta Therapeutics Inc – Key Employees 48
Sarepta Therapeutics Inc – Locations And Subsidiaries 49
Head Office 49
Other Locations & Subsidiaries 49
Recent Developments 50
Strategy And Business Planning 50
Jun 27, 2017: Sarepta Therapeutics Announces Grand Opening of its Research and Manufacturing Center at Andover 50
Financial Announcements 51
Oct 25, 2018: Sarepta Therapeutics announces third quarter 2018 financial results and recent corporate developments 51
Aug 08, 2018: Sarepta Therapeutics announces second quarter 2018 financial results and recent corporate developments 55
May 03, 2018: Sarepta Therapeutics Announces First Quarter 2018 Financial Results and Recent Corporate Developments 60
Mar 01, 2018: Sarepta Therapeutics Announces Fourth Quarter 2017 and Full-Year 2017 Financial Results and Recent Corporate Developments 63
Oct 25, 2017: Sarepta Therapeutics Announces Third Quarter 2017 Financial Results and Recent Corporate Developments 66
Jul 19, 2017: Sarepta Therapeutics Announces Second Quarter 2017 Financial Results and Recent Corporate Developments 68
Apr 27, 2017: Sarepta Therapeutics Announces First Quarter 2017 Financial Results and Recent Corporate Developments 70
Feb 28, 2017: Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2016 Financial Results and Recent Corporate Developments 71
Corporate Communications 73
Jun 07, 2018: Sarepta Therapeutics Appoints Gilmore O’Neill, M.B., M.M.Sc. as Chief Medical Officer 73
Dec 05, 2017: Sarepta Therapeutics Elects Biopharmaceutical Veteran, Michael W. Bonney, to its Board of Directors 74
Sep 25, 2017: Sarepta Therapeutics Appoints Guriqbal S. Basi, Ph.D. as Chief Scientific Officer 75
Apr 05, 2017: Sarepta Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) 76
Apr 03, 2017: Sarepta Therapeutics Announces Appointment of Catherine Stehman-Breen, M.D., M.S. as Chief Medical Officer 77
Mar 30, 2017: Sarepta Therapeutics Announces Addition of Kenneth Fischbeck, M.D. and Matthew Wood M.D., Ph.D. to the Company’s Strategic and Scientific Advisory Board 78
Government and Public Interest 79
Apr 10, 2018: Advocacy groups urge US government to lower price of costly DMD drug 79
Product News 80
11/07/2017: Sarepta Therapeutics Announces FDA Clearance of IND for the Company’s PPMO Exon 51 Candidate, SRP-5051 80
09/06/2017: Sarepta Therapeutics Announces Positive Results in Its Study Evaluating Gene Expression, Dystrophin Production, and Dystrophin Localization in Patients with Duchenne Muscular Dystrophy (DMD) Amenable to Skipping Exon 53 Treated with Golodirsen (SRP-4053) 81
Product Approvals 83
Nov 03, 2017: Sarepta Therapeutics and Nationwide Children’s Hospital Announce U.S. Food and Drug Administration (FDA) Clearance of the IND Application for the GALGT2 Gene Therapy Program 83
Other Significant Developments 84
Jun 25, 2018: Decode Duchenne Announces 1,000th Patient Application 84
Appendix 85
Methodology 85
About GlobalData 85
Contact Us 85
Disclaimer 85
Sarepta Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Sarepta Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Sarepta Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Sarepta Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Sarepta Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Sarepta Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Sarepta Therapeutics to Acquire Manufacturing Plant in Massachusetts from Eisai for USD15 Million 12
InVitae Expands Partnership with Sarepta Therapeutics 13
Sarepta Therapeutics Enters into Partnership with Myonexus Therapeutics 14
Sarepta Therapeutics Enters into Research Agreement with Duke University 15
Sarepta Therapeutics Enters into Research Agreement with Genethon 16
Sarepta Therapeutics Enters into Research Agreement with Nationwide Children's Hospital 17
Catabasis Pharma Enters into Agreement with Sarepta Therapeutics 18
Murdoch University Enters into Research Agreement with Sarepta Therapeutics 19
Sarepta Therapeutics Enters into Agreement with Flagship Biosciences 20
Sarepta Therapeutics Enters Into Co-Development Agreement With University College London 21
Sarepta Therapeutics Enters into License Agreement with Lysogene 22
Sarepta Therapeutics to Enter into Option Agreement with Nationwide Children's Hospital 23
Sarepta Therapeutics Enters into Licensing Agreement with Lacerta Therapeutics 24
Sarepta Therapeutics Enters into Licensing Agreement with BioMarin Pharma 25
Sarepta Therapeutics Enters into Licensing Agreement with Nationwide Children's Hospital 27
Sarepta Therapeutics Enters into Licensing Agreement with Summit Therapeutics 28
Sarepta Therapeutics Enters Into Licensing Agreement With University Of Western Australia For Duchenne Muscular Dystrophy 29
Sarepta Therapeutics to Raise USD500 Million in Public Offering of Shares 31
Sarepta Therapeutics Prices Public Offering of Shares for USD325 Million 32
Sarepta Therapeutics Prices Public Offering of Shares for USD300 Million 34
Sarepta Therapeutics to Raise USD37.5 Million in Public Offering of Shares 36
Sarepta Therapeutics Raises USD126.8 Million in Public Offering of Shares 37
Sarepta Therapeutics Completes Public Offering Of Shares For US$100.7 Million 39
Sarepta Therapeutics Raises USD125 million in Public Offering Of Shares 41
Sarepta Therapeutics Completes Public Offering Of Common Stock For US$125 Million 42
Sarepta Therapeutics Completes Private Placement Of Shares 44
Sarepta Therapeutics Announces Exercise of Initial Purchasers’ Option for USD95 Million in Private Placement of Notes Due 2024 45
Sarepta Therapeutics Sells Pediatric Disease Priority Review Voucher 46
Sarepta Therapeutics Inc, Key Competitors 47
Sarepta Therapeutics Inc, Key Employees 48
Sarepta Therapeutics Inc, Subsidiaries 49
List of Figures
Sarepta Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Sarepta Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Sarepta Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Sarepta Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Sarepta Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Sarepta Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Sarepta Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Sarepta Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9